Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment
2024-04-19
免疫疗法临床结果专利侵权
Plus, news about TScan Therapeutics:
Histogen files for Chapter 11 bankruptcy:
The biotech, which stopped work in September,
filed
a petition with the US Bankruptcy Court for the Southern District of California. Its next steps include confirming a plan of liquidation to distribute value to stakeholders.
— Ayisha Sharma
Barinthus Bio touts Ph1b/2 HPV data:
The company’s immunotherapy candidate, VTP-200,
met
the primary safety endpoint in a trial of 108 women with high-risk HPV-associated low-grade cervical lesions. The group with the highest treatment dose achieved a 60% high-risk HPV clearance rate at 12 months versus a 33% clearance rate for placebo.
— Ayisha Sharma
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-药物
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。